Residency · Residency · Medical Genetics Genomics

Preemptive Pharmacogenomic Testing: Implementation and Barriers

Introduction

Preemptive pharmacogenomic (PGx) testing involves genotyping patients for clinically actionable pharmacogenes before a relevant drug is prescribed, storing results in the electronic health record (EHR) for future clinical decision support. This proactive model contrasts with reactive testing, where genotyping occurs only at the point of prescribing. Multiple academic medical centers have demonstrated the feasibility and clinical value of preemptive PGx programs.

Rationale for Preemptive Testing

Over 90% of individuals carry at least one actionable pharmacogenomic variant. Reactive testing introduces delays at the point of prescribing when results are needed urgently. Pharmacogenomic genotypes are stable throughout life, meaning a single test provides lifelong utility. Multiple gene-drug interactions can be addressed from a single testing event, and preemptive results are available at every future prescribing encounter across all specialties.

Key Implementation Programs

Pioneering Institutional Programs

PREDICT (Vanderbilt) was one of the earliest programs, integrating a preemptive PGx panel into clinical care since 2010 and demonstrating feasibility of EHR-embedded clinical decision support. RIGHT (Mayo Clinic) established the Right Drug, Right Dose, Right Time protocol with preemptive genotyping and EHR-integrated alerts. PG4KDS (St. Jude Children's Research Hospital) is a pediatric oncology-focused program where all patients receive preemptive PGx testing at the start of therapy. The IGNITE (Implementing Genomics in Practice) Network is a multi-site NIH-funded network evaluating genomic medicine implementation including PGx.

National and International Initiatives

The Netherlands DPWG (Dutch Pharmacogenetics Working Group) has integrated PGx guidelines into national drug information systems. CPIC provides freely available, evidence-based guidelines for gene-drug pairs and is harmonizing with DPWG. The European Medicines Agency (EMA) mandated DPYD testing before fluoropyrimidine prescribing in the EU in 2020. The Ubiquitous Pharmacogenomics (U-PGx) Consortium conducted the European multi-center PREPARE study demonstrating a 30% reduction in actionable ADRs with preemptive PGx panel testing.

Implementation Components

Testing Panel Design

Core genes typically include CYP2D6, CYP2C19, CYP2C9, CYP3A5, DPYD, TPMT, NUDT15, SLCO1B1, VKORC1, UGT1A1, HLA-B, HLA-A, and IFNL3/4. Panel selection is guided by CPIC Level A gene-drug pairs (strong evidence, actionable), with currently over 20 such pairs. Genotyping platforms include array-based systems (such as Illumina Global Screening Array with PGx content), targeted sequencing panels, and commercial PGx platforms.

Clinical Decision Support (CDS)

EHR integration is essential, with results stored as discrete, structured data. Active CDS alerts are triggered at the point of prescribing when a drug-gene interaction exists. Alerts must be specific, actionable, and non-interruptive for low-risk interactions to avoid alert fatigue. Interruptive (hard-stop) alerts are reserved for highest-risk interactions (such as codeine in CYP2D6 UMs in pediatrics). Pre-test and post-test educational resources for prescribers are embedded in the EHR.

Reporting and Documentation

Results are reported using standardized diplotype and phenotype terminology (CPIC consensus). Phenotype (such as CYP2D6 poor metabolizer) is linked to specific prescribing recommendations. Results must persist in the medical record and be accessible across clinical encounters. Interoperability standards including HL7 FHIR PGx implementation guides enable cross-system data exchange.

Evidence for Clinical Impact

Clinical Outcomes

The PREPARE study (U-PGx) demonstrated a 30% reduction in clinically relevant ADRs with preemptive PGx panel testing versus standard care. Vanderbilt PREDICT showed that over 90% of patients had a clinically actionable PGx variant, with CDS alerts altering prescribing in a significant proportion of encounters. St. Jude PG4KDS changed therapy in approximately 7% of prescribing events and prevented potential ADRs.

Cost-Effectiveness

Multiple analyses demonstrate cost-effectiveness when panel testing replaces single-gene reactive testing. Results are most favorable when applied to populations with high likelihood of encountering actionable drugs (such as psychiatry, cardiology, and oncology patients). Panel testing cost has decreased to $200-500 per patient and is expected to continue declining. Long-term savings accrue from prevented ADRs, reduced hospitalizations, and optimized drug selection.

Barriers to Implementation

Technical Barriers

CYP2D6 complexity requires specialized genotyping methods beyond standard array-based approaches due to structural variation. EHR integration demands significant informatics investment to build and maintain CDS systems. Interoperability challenges mean PGx results must be portable across health systems using still-maturing standards. Translating star allele nomenclature into standardized clinical terms remains challenging.

Clinical Barriers

Provider knowledge gaps are common, as many prescribers lack training in PGx interpretation, making education essential. Alert fatigue from excessive or poorly designed alerts leads to override behavior. Uncertain clinical utility persists for some gene-drug pairs lacking strong outcome data. The misconception that a "normal metabolizer" result guarantees drug efficacy or safety must be addressed.

Systemic Barriers

Insurance coverage for preemptive panels is inconsistent and often requires prior authorization. The regulatory framework involves varying requirements depending on whether tests are classified as laboratory-developed tests or FDA-cleared assays. Access disparities exist by geography, socioeconomic status, and race/ethnicity. Return of results raises questions about incidental findings from broad genotyping panels.

Ethical Considerations

Informed consent must communicate the scope of preemptive testing and potential incidental findings. Genetic information is subject to GINA protections but with gaps in life insurance and long-term care coverage. The duty to recontact raises questions about whether prior results should be re-evaluated as new gene-drug associations emerge.

Future Directions

Integration of PGx into primary care and community pharmacy settings is advancing. Point-of-care PGx testing enables rapid turnaround in acute settings. Whole genome sequencing-derived PGx extracts pharmacogenomic results from clinical WGS/WES data. Polygenic PGx scores move beyond single-gene approaches to capture complex pharmacogenomic architecture. National implementation programs modeled on the All of Us Research Program PGx initiative are expanding access.

Clinical Pearls

Over 90% of individuals carry at least one actionable PGx variant, making preemptive testing broadly relevant rather than targeted to specific populations. Effective clinical decision support integrated into the EHR is the critical success factor; without it, PGx results sit unused in the chart. Alert design must balance specificity and actionability against the risk of alert fatigue that leads to universal overriding. The PREPARE trial provides the strongest evidence to date that preemptive PGx panel testing reduces clinically relevant adverse drug reactions.

References

1. Swen JJ, van der Wouden CH, Manson LE, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401(10380):347-356.
2. Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annual Review of Pharmacology and Toxicology. 2015;55:89-106.
3. Relling MV, Klein TE, Gammal RS, et al. The Clinical Pharmacogenetics Implementation Consortium: 10 years later. Clinical Pharmacology & Therapeutics. 2020;107(1):171-175.
4. Weitzel KW, Cavallari LH, Lesko LJ. Preemptive panel-based pharmacogenetic testing: the time is now. Pharmaceutical Research. 2017;34(8):1551-1555.

Read this lecture as Markdown